- Speaker presentation
- Open Access
Unlocking the chemistry of bile acids for cancer therapeutics
© Bajaj; licensee BioMed Central Ltd. 2014
- Published: 21 January 2014
- Breast Cancer
- Bile Acid
- Drug Carrier
- Cholic Acid
Breast cancer is the second leading cause of cancer deaths today after lung cancer and is the most common cancer among women. The primary drug tamoxifen is used treat breast cancer has several problems including poor oral bioavailability. Bile acids/salts are known to be components of endogenous molecular pool that solubilizes, absorbs dietary fat/lipid molecules in the form of micelles. Bile acids are interesting chemical scaffold for drug conjugation due to presence of different number of free hydroxyl groups and a free carboxylic acid. We have been exploring bile acids as drug carriers for cancer therapy. We used three bile acids: lithocholic acid (LCA), deoxycholic acid (DCA) and cholic acid (CA) to engineer bile acid tamoxifen conjugates with free amine and acid functionalities. In this talk, I would present the interactions of these new drug carriers and their therapeutic potential for breast cancer therapy.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.